 BidaskClub cut shares of Denali Therapeutics NASDAQ:DNLI from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, BidAskClub reports. Other equities research analysts have also recently issued reports about the stock. Nomura reissued a buy rating and issued a 35.00 price target on shares of Denali Therapeutics ... 